Latest news

ENYO Pharma pursues its international strategy and opens a new subsidiary in Australia

ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.

Read more »

MIMESIS: a novel systems biology approach to develop preclinical assets

MIMESIS NEWSLETTER #1, April 2017

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.

Read more »

A new collaboration studying the impact of FXR function on HBV replications

ENYO Pharma is pleased to announce the initiation of a collaboration with the group of Professor Patrice André (Inserm U1111, Lyon, France) to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). In addition to identifying opportunities for new anti-HBV therapeutics, this collaboration will strengthen understanding of the mode of action of EYP001, ENYO’s lead compound. EYP001 is a highly selective FXR modulator that reduces the HBV cccDNA reservoir,

Read more »

ENYO Pharma receives Tranche 2 of its Series A investment.

ENYO Pharma has received the 10 M€ Tranche 2 of its Series A investment. The Board of Directors unanimously requested the Investors release this second Tranche of the 22 M€ Series A which closed in January 2016. This release is a response to several successfully achieved milestones, most importantly the Board decision to initiate Phase 1b in chronically infected, HBV patients. The first patients enrolment is planned for Q2 2017.

Read more »